Created with sketchtool.

Risk of Recurrence
Risk of Recurrence

Just 1 risk factor further increases risk of recurrence4-10

RISK CONSIDERATIONS IN HER2+ EARLY BREAST CANCER PATIENTS

1 or more positive nodes

  • At 10 years, 25% of patients with 1–3 positive nodes experienced recurrence4
  • At 10 years, 45% of patients with ≥4 positive nodes experienced recurrence4

Tumor diameter ≥2 cm

  • Tumors 2 cm to 5 cm in diameter were associated with a 53% increase in the risk of recurrence5,*
  • Tumors >5 cm in diameter were associated with an 81% increase in the risk of recurrence5,*

Overall risk of recurrence increases over time†

  •  The risk of recurrence increased ~3% annually on average in HER2+ patients after receiving trastuzumab-based therapy4,5
  •  Recurrence may occur later in HR+ patients, putting younger women with HER2+, HR+ disease at increasing long-term risk6

Other risk factors include:

  •  Age at diagnosis7
  •  Smoking9
  •  High BMI8
  •  Lack of pCR10

BMI: body mass index; HER: human epidermal growth factor receptor; HR+: hormone receptor-positive; pCR: pathologic complete response.

*Compared with tumors less than 2 cm in diameter.

†Recurrence refers to disease-free survival over 10 years, defined as the time from enrollment to documentation of the first of any of these events: local, regional, or distant recurrence of breast cancer; a contralateral breast cancer; a second primary cancer; or death as a result of any cause.

Monoclonal antibodies have improved but not eliminated the risk of recurrence4,5,11-13

RECURRENCE RATES IN HER2+ EARLY BREAST CANCER CLINICAL TRIALS

Once distant recurrence has occurred, the disease remains largely incurable and patient survival is low14,15

Learn about NERLYNX for
early-stage HER2+ breast cancer

AC: anthracycline plus cyclophosphamide; HER: human epidermal growth factor receptor; ITT: intent to treat; pCR: pathologic complete response; T: taxane; TC: taxane plus carboplatin.

*Recurrence refers to disease-free survival, defined as the time from randomization to the first occurrence of any of these events: recurrence of breast cancer at any site; the development of ipsilateral or contralateral breast cancer, including ductal carcinoma in situ but not lobular carcinoma in situ; second nonbreast malignant disease other than basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix; or death from any cause.4

†Recurrence refers to disease-free survival, defined as the time from enrollment to documentation of the first of any of these events: local, regional, or distant recurrence of breast cancer; a contralateral breast cancer; a second primary cancer; or death as a result of any cause.5

‡Recurrence refers to disease-free survival, defined as the time from randomization to breast cancer recurrence, a second primary cancer (excluding contralateral ductal carcinoma in situ), or death from any cause.12

§Recurrence refers to invasive disease–free survival, defined as time from randomization to the first occurrence of any of the following events: recurrence of ipsilateral invasive breast tumor, recurrence of ipsilateral locoregional invasive breast cancer, contralateral invasive breast cancer, a distant disease recurrence, or death from any cause.13

Preventing CNS metastases remains a critical unmet need in HER2+ breast cancer16,17

katherine trial

(trastuzumab emtansine)

56%

of patients who experienced DISTANT recurrence had CNS metastases as the first site of recurrence (44/78)

APHINITY TRIAL

(pertuzumab)

35%

OF PATIENTS WHO EXPERIENCED DISTANT RECURRENCE HAD CNS METASTASES AS THE FIRST SITE OF RECURRENCE (49/141)

Trastuzumab emtansine did not reduce the incidence of CNS metastases16
  • 6.1% of patients had CNS recurrence with trastuzumab emtansine vs 5.4% with trastuzumab
In patients with CNS recurrence, median OS was numerically lower in the trastuzumab emtansine arm vs trastuzumab16
  • Median OS of 12.5 months with trastuzumab emtansine vs 14.3 months with trastuzumab
Overall, up to 50% of patients with advanced HER2+ breast cancer will develop brain metastases18-20
CNS: central nervous system; HER: human epidermal growth factor receptor; OS: overall survival.
Learn more about an option for HER2+ breast cancer

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥5% of patients) were:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.

You are leaving this website

By clicking this link, you will be leaving the NERLYNX website and will be redirected to another webpage.

Yes, leave this website

Reference:

  1. Gnant M, Martin M, Holmes FA, et al. Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early stage breast cancer: subgroup analyses from the phase III ExteNET trial. Poster presented at: 2018 San Antonio Breast Cancer Symposium (SABCS); December 4-8, 2018; San Antonio, TX.
  2. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-1700.
  3. NERLYNX (neratinib) tablets Prescribing Information, Puma Biotechnology, Inc. 04/20.
  4. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195-1205.
  5. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752.
  6. Strasser-Weippl K, Horick N, Smith IE, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17:56.
  7. Recurrent breast cancer. Mayo Clinic website. https://www.mayoclinic.org/diseases-conditions/recurrent-breast-cancer/symptoms-causes/syc-20377135. Accessed February 11, 2020.
  8. Sun L, Zhu Y, Qian Q, Tang L. Body mass index and prognosis of breast cancer: an analysis by menstruation status when breast cancer diagnosis. Medicine (Baltimore). 2018;97(26):e11220.
  9. Pierce JP, Patterson RE, Senger CM, et al. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. J Natl Cancer Inst. 2014;106(1):djt359.
  10. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 trial—CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012;30(26):3242-3249.
  11. Helwick C. Final analysis of BCIRG-006 supports use of non–anthracycline-containing regimen in treatment of women with early breast cancer. The ASCO Post website. https://www.ascopost.com/issues/march-10-2016/final-analysis-of-bcirg-006-supports-use-of-nonanthracycline-containing-regimen-in-treatment-of-women-with-early-breast-cancer. Accessed February 11, 2020.
  12. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
  13. Von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628.
  14. Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014;111(10):1888-1898.
  15. Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834-4843.
  16. Untch M, Geyer CE Jr, Huang C-S, et al. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Slides presented at: 2019 European Society for Medical Oncology (ESMO) Annual Meeting; September 30, 2019; Barcelona, Spain.
  17. Chien J. HER2+ early breast cancer: balancing risk and toxicity. Slides presented at: 2019 San Antonio Breast Cancer Symposium (SABCS); December 11, 2019; San Antonio, TX.
  18. Lin NU. Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience. 2013;7:307.
  19. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007;13(6):1648-1655.
  20. Olson EM, Najita JS, Sohl J, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22(4):525-531.
  21. Hegedüs C, Truta-Feles K, Antalffy G, et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. Biochem Pharmacol. 2012;84(3):260-267.
  22. Puma Biotechnology, Inc. Data on file. 02/20.
  23. Chan A, Hurvitz SA, Marx G, et al. Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early-stage breast cancer: phase II CONTROL trial. Poster presented at: 2019 San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2019; San Antonio, TX.
  24. Puma Biotechnology. FDA ODAC Sponsor Presentation. May 24, 2017.
  25. National Cancer Institute, National Institute of Health, US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised version 4.03 June 14, 2010.
  26. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.3.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 6, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.
  27. XELODA [package insert]. South San Francisco, CA: Genentech USA, Inc.
  28. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 10, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.
  29. Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081-1089.
  30. Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2(12):1557-1564.
  31. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958-3965.
  32. Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim). 2008;341(8):465-477.
  33. Canonici A, Gijsen M, Mullooly M, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4(10):1592-1605.
  34. Zhao XQ, Xie JD, Chen XG, et al. Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol. 2012;82(1):47-58.
  35. Collins DM, Conlon NT, Kannan S, et al. Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer. Cancers (Basel). 2019;11(6):E737.
  36. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 2008;5(9):531-542.
  37. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15(24):7479-7491.
  38. Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implication. Breast Care. 2013;8:256-262.
  39. Chung A, Cui X, Audeh W, Giuliano A. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer. 2013;13(4):223-232.
  40. Paplomata E, Nahta R, O'Regan RM. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach? Cancer. 2015;121(4):517-526.
  41. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217-233.
  42. Loi S, Dafni U, Karlis D, et al. Effects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA trial. JAMA Oncol. 2016:2(8):1040-1047.

    This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.

    I am a Healthcare Professional in the US I am a Patient or Caregiver in the US, 18 years of age or older